XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Tables)

Condensed Consolidated Financial Statement Detail (Tables)

9 Months Ended

Sep. 30, 2014

Condensed Consolidated Financial Statement Detail [Abstract]

Outstanding securities considered anti-dilutive

The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Common stock options and restricted stock units		8,037		6,825		6,601		6,017
Warrants for common stock		1,910		15,970		1,910		16,106
Total		9,948		22,795		8,511		22,123

Reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock

For the three and nine months ended September 30, 2014, the following is a reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock (in thousands):

	Three months ended September 30,			Nine months ended September 30,
	2014			2014
Numerator
Net loss before taxes
Basic	$	(14,399	)	$	(30,983	)
Adjustment for revaluation of contingent warrant liabilities		5,360			32,510
Diluted	$	(19,759	)	$	(63,493	)
Denominator
Weighted average shares outstanding used for basic net loss per share		107,208			106,768
Effect of dilutive warrants		7,115			8,108
Weighted average shares outstanding and dilutive securities used for diluted net income per share		114,323			114,876

Accrued liabilities

Accrued liabilities consisted of the following at September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014		December 31, 2013
Accrued payroll and other benefits	$	2,928	$	3,009
Accrued management incentive compensation		3,187		4,386
Other		1,388		2,539
Total	$	7,503	$	9,934